- Home
- SDST vs APLT Comparison
SDST vs APLT Comparison
Compare SDST & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SDST
- APLT
- Stock Information
- Founded
- SDST 2022
- APLT 2016
- Country
- SDST United States
- APLT United States
- Employees
- SDST N/A
- APLT N/A
- Industry
- SDST Blank Checks
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- SDST Finance
- APLT Health Care
- Exchange
- SDST Nasdaq
- APLT Nasdaq
- Market Cap
- SDST 37.0M
- APLT 44.0M
- IPO Year
- SDST N/A
- APLT 2019
- Fundamental
- Price
- SDST $0.53
- APLT $0.48
- Analyst Decision
- SDST Buy
- APLT Buy
- Analyst Count
- SDST 2
- APLT 7
- Target Price
- SDST $1.70
- APLT $6.10
- AVG Volume (30 Days)
- SDST 26.0M
- APLT 2.5M
- Earning Date
- SDST 08-15-2025
- APLT 08-06-2025
- Dividend Yield
- SDST N/A
- APLT N/A
- EPS Growth
- SDST N/A
- APLT N/A
- EPS
- SDST N/A
- APLT N/A
- Revenue
- SDST N/A
- APLT $265,000.00
- Revenue This Year
- SDST N/A
- APLT $415.60
- Revenue Next Year
- SDST $246.67
- APLT $1,323.96
- P/E Ratio
- SDST N/A
- APLT N/A
- Revenue Growth
- SDST N/A
- APLT N/A
- 52 Week Low
- SDST $0.14
- APLT $0.30
- 52 Week High
- SDST $17.62
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- SDST N/A
- APLT 60.46
- Support Level
- SDST N/A
- APLT $0.44
- Resistance Level
- SDST N/A
- APLT $0.55
- Average True Range (ATR)
- SDST 0.00
- APLT 0.04
- MACD
- SDST 0.00
- APLT 0.01
- Stochastic Oscillator
- SDST 0.00
- APLT 68.60
About SDST Stardust Power Inc. Common Stock
Stardust Power Inc is developing a lithium refinery at its Facility in Muskogee, Oklahoma, with planned capacity of producing up to 50,000 metric tons per annum of BGLC once fully operational. The company will source lithium brine feedstock from various suppliers and may make investments upstream to secure additional feedstock. The Company seeks to sell its products to electric vehicle (EV) manufacturers as the primary market, with potential applications in other areas such as battery manufacturers, the U.S. military, and original equipment manufacturers (OEMs).
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.